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Abstract
Background: Low nitric oxide (NO) bioavailability plays a role in the pathogenesis of human as well as of experimental
cerebral malaria (ECM) caused by Plasmodium berghei ANKA (PbA). ECM is partially prevented by administration of the NO-
donor dipropylenetriamine NONOate (DPTA-NO) at high concentration (1 mg/mouse), which also induces major side effects
such as a sharp drop in blood pressure. We asked whether alternative strategies to improve NO bioavailability with minor
side effects would also be effective in preventing ECM.
Methodology/Principal Findings: Mice were infected with PbA and prophylactically treated twice a day with bolus
injections of L-arginine, Nv-hydroxy-nor-Arginine (nor-NOHA), tetrahydrobiopterin (BH4), separately or combined, sodium
nitrite, sildenafil or sildenafil plus DPTA-NO starting on day 0 of infection. L-arginine and BH4 supplementation, with or
without arginase inhibition by nor-NOHA, increased plasma nitrite levels but failed to protect against ECM development.
Accordingly, prophylactic treatment with continuous delivery of L-arginine using osmotic pumps also did not improve
survival. Similar outcomes were observed with sodium nitrite sildenafil (aimed at inhibiting phosphodiesterase-5) or with
DPTA-NO. However, sildenafil (0.1 mg/mouse) in combination with a lower dose (0.1 mg/mouse) of DPTA-NO decreased
ECM incidence (8267.4% mortality in the saline group and 38610.6% in the treated group; p,0.05). The combined
prophylactic therapy did not aggravate anemia, had delayed effects in systolic, diastolic and mean arterial blood pressure
and induced lower effects in pulse pressure when compared to DPTA-NO 1 mg/mouse.
Conclusions/Significance: These data show that sildenafil lowers the amount of NO-donor needed to prevent ECM,
resulting also in lesser side effects. Prophylactic L-arginine when given in bolus or continuous delivery and bolus BH4
supplementation, with or without arginase inhibition, were able to increase NO bioavailability in PbA-infected mice but
failed to decrease ECM incidence in the doses and protocol used.
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Introduction
Human cerebral malaria (HCM) is a life-threatening condition
and remains a serious public health problem in a number of
tropical and sub-tropical countries [1]. Despite anti-malarial
treatment, the disease has a significant mortality rate of 18–30%
and a significant proportion of children who survive are left with
cognitive disability (,25%) and neurologic deficits (1.1–4.4%), for
which there is often very little long-term support or treatment
[2,3,4,5,6].
The murine model of cerebral malaria induced by Plasmodium
berghei ANKA (PbA) in susceptible mouse strains is considered to
present a number of similarities with HCM in terms of
physiopathogenesis. It is also thought to present a number of
differences and therefore there is no consensus to its relevance to
HCM [7,8,9,10,11,12,13]. However, low nitric oxide (NO)
bioavailability is believed to play a significant role in both HCM
and murine or experimental cerebral malaria (ECM). ECM is
associated with a microvascular dysfunction in the brain char-
acterized by vasoconstriction, vascular occlusion, endothelial
activation with intravascular inflammation, microhemorrhages
and eventually vascular collapse [14,15]. Endothelial dysfunction
is at least in part explained by a state of low NO bioavailability in
PbA-infected mice that has been argued to result mainly from the
low plasma levels of L-arginine [16], the substrate used by the NO
synthases (NOS) to generate NO plus citrulline [17,18], as well as
from the NO-scavenging effect of cell-free hemoglobin due to
parasite-induced hemolysis [16]. Similarly, patients with severe
malaria, including HCM, show low levels of exhaled NO,
endothelial dysfunction [19], reduced endothelial NO synthase
PLoS ONE | www.plosone.org 1 February 2012 | Volume 7 | Issue 2 | e32048expression [20], hypoargininemia [19,21], and increased levels of
acellular plasma hemoglobin [22].
Prophylactic treatment of PbA-infected mice with the NO-
donor dipropylenetriamine NONOate (DPTA-NO) can partially
prevent ECM development [15,16]. However, DPTA-NO has
been shown to ameliorate microvascular dysfunction and prevent
ECM development only at high concentrations (1 mg/mouse
every 12 hours) with the generation of NO levels well above those
attained under physiological conditions [16]. These high levels
induce important side effects such as marked hypotension [16] and
worsening of the infection-induced anemia [15]. Therefore, It
remains to be shown whether more physiologically and clinically
relevant strategies to improve NO bioavailability are also effective
in preventing ECM development while generating less significant
side effects.
Several factors may help to explain the states of low NO
bioavailability and hypoargininemia that occur during ECM,
consequently a number of interventions can be devised to correct
these deficiencies. In addition to releasing hemoglobin, hemolysis
may also release large amounts of arginase, which competes with
NOS for the same substrate, L-arginine, depleting its endogenous
pools and generating urea plus ornithine rather than NO [23,24].
Arginine supplementation, with or without arginase inhibition, is
therefore expected to improve NO bioavailability. Interestingly,
although clinical trials with L-arginine infusion have been
performed in malaria endemic areas and showed that it ameliorates
malaria-related endothelial dysfunction and is safe [19,25], this
approach has not been explored in ECM. On the other hand, even
in the presence of proper amounts of substrate, NOS malfunction
may occur and result in decreased production of NO. In fact, a
decrease of NOS activity in the brain has been shown in PbA-
infected moribund mice [26,27]. NOS is a homodimeric oxidore-
ductase containing heme, flavin adenine dinucleotide, flavin
mononucleotide,and tetrahydrobiopterin(BH4), whichis acofactor
essential for the catalytic activity of three major NOS isoforms:
neuronal (nNOS), inducible (iNOS), and endothelial (eNOS) [17].
The coupling between the NO substrate, L-arginine, and the heme
site requires BH4 to bind in the dimer interface of NOS. BH4
depletion, which results from its oxidation and/or reduced
synthesis, causes functional uncoupling of NOS, which results in
the generation of more superoxide and less NO [28]. In this case,
BH4 supplementation may improve NOS function.
One alternative strategy to overcome the low NO bioavailability
in ECM without boosting NO generation is to maximize signaling
by the available NO. The most studied and well characterized
pathway by which NO can exercise its biological effects is through
soluble guanylyl cyclase (sGC) activation, resulting in increased
levels of cyclic guanosine monophosphate (cGMP) [17]. cGMP
levels are decreased by 60% in the brain of mice with ECM and
prophylactic administration of DPTA-NO can restore them to
values encountered in uninfected animals [16]. In healthy states,
tissue cGMP levels are determined by a balance between the
activities of sGC and cyclic nucleotide phosphodiesterases (PDEs)
that catalyze the breakdown of cGMP [29]. Drugs such as
sildenafil increase brain cGMP levels through inhibition of PDE-5
and therefore prolong the downstream effects of NO, providing for
improved NO activity without changing NO generation [30].
Therefore, sildenafil administration alone or coupled with lower
doses of NO-donors such as DPTA-NO itself might be expected to
magnify the effects of limited endogenous NO production and
prevent ECM without causing the marked side effects observed
with high doses of DPTA-NO.
Finally, alternative NO donors could be considered. It has been
experimentally [31,32] and clinically [33,34] shown that deoxygenated
hemoglobin in an acidic environment reduces nitrite to NO causing
vasodilation. This effect may have an important function in providing
NO in sites of low oxygenation, such as in ischemia. Since we have
previously shown that ECM is associated with vasospasm, decreased
b l o o df l o w ,a n dr e g i o n a lh y p o p e r f u s i o ni nt h eb r a i n[ 1 4 ] ,w e
anticipated that administration of sodium nitrite to PbA-infected mice
might lead to endogenous NO generation and amelioration of the
microcirculatory dysfunction decreasing mortality.
In the present study, we evaluated the efficacy and safety of
these different strategies, independently or in combination, in
preventing the development of ECM and improving NO
bioavailability during the infection by P. berghei ANKA. We
show that none of the strategies aimed to increase the endogenous
production of NO by NOS, or boost its effects through the sGC
pathway, were efficient to prevent ECM. We also show that lower
doses of DPTA-NO did not prevent ECM, but protection was
obtained when this strategy was combined with PDE-5 inhibition
by sildenafil. Finally, we show that the combined therapy did not
produce all the adverse side effects generated by the prophylactic
treatment with high doses of DPTA-NO alone.
Materials and Methods
Mice, parasites and infection
This study was carried out in strict accordance with the
recommendations in the Guide for the Care and Use of
Laboratory Animals of the National Institutes of Health. All
experimental protocols were reviewed and approved by LJBI’s
Institutional Animal Care and Use Committee (Permit Number:
NO-Heme 001) and all efforts were made to minimize suffering.
Six to eight week old C57BL/6 mice (18–20 g) were obtained
from Jackson Laboratories (Bar Harbor, ME). Mice were housed
in groups of no more than five per cage with free access to chow
and water and allowed to adapt to their new environment for three
days before experimentation. The Plasmodium berghei ANKA
PbA-GFPcon 259cl2, which is a genetically modified parasite of
clone cl15cy1 of the ANKA strain that expresses GFP constitu-
tively during the whole life cycle, was used (a kind donation of
MR4, Manassas, VA; deposited by CJ Janse and AP Waters; MR4
reagent number: MRA-865). The parasite was propagated in
C57BL/6J mice and in each experiment a fresh blood sample was
obtained from a passage mouse and a suspension containing
1610
6 parasitized red blood cells (pRBC) in 100 mL was injected
intraperitoneally (IP) in each mouse of the experimental groups.
Parasitemia was checked using flow cytometry and quantified by
counting the number of pRBC in 10,000 RBC beginning on day 4
after infection.
Clinical assessment
Motor behavior and rectal temperature were checked daily as
described before [35]. Briefly, a set of six simple behavioral tests
(transfer arousal, locomotor activity, tail elevation, wire maneuver,
contact righting reflex and righting in arena) adapted from the
SHIRPA protocol [36,37] was used to provide a better estimate of
the overall clinical status of the mice during infection. The
performance in each test was assessed and a composite score was
determined ranging from 0 to 23, where 23 indicates maximum
performance and 0 indicates complete impairment – usually coma.
Body temperature was monitored using an Accorn Series
Thermocouple thermometer with a mouse rectal probe (Oakton
Instruments, Vernon Hills, IL). ECM was defined as the
presentation of one or more of the following clinical signs of
neurological involvement: ataxia, limb paralysis, poor righting
reflex, seizures, roll-over, coma.
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PbA-infected mice were treated with either saline, dipropylene-
triamine NONOate (DPTA-NO, Cayman Chemical, Ann Arbor,
MI – 0.01, 0.1 and 1 mg/mouse), L-arginine (Sigma-Aldrich, St.
Louis, MO – 4 mg/mouse), tetrahydro-L-Biopterin (BH4, Cay-
man Chemical – 1 mg/mouse), Nv-hydroxy-nor-Arginine (nor-
NOHA, Bachem, Torrance, CA – 250 mg/mouse), sildenafil
(Sigma-Aldrich, 0.001, 0.01 and 0.1 mg/mouse), NaNO2 (Sigma-
Aldrich, 0.72 mg/mouse), and selected combinations of these
drugs via IP, twice a day starting on day 0. All drugs were diluted
in saline and a total volume of 100 ml/mouse per dose was injected
per treatment. L-arginine dosing was based in a previous human
malaria study showing that a similar dose (12 g, or approximately
200 mg/kg) improved endothelial function in patients with
moderately severe falciparum malaria [19]. In healthy rats,
intravenous injection of L-arginine induces a rapid and transient
(60 minutes) increase in plasma levels, but arginine levels in the
brain remain elevated for more than 8 hours [38,39]. Oral
supplementation with 10 mg/kg/day of BH4 prevents endothelial
dysfunction in murine models of non malarial pathologies with
chronic vascular oxidative stress [40,41], but doses as high as
50 mg/Kg IP twice a day were used and well tolerated [42]. As
administration of BH4 in the presence of conditions with increased
oxidative stress may lead to its rapid oxidative degradation and
thus limited duration of the beneficial effects [43], we used a high
dose in our experiments. Nor-NOHA is a potent arginase inhibitor
and the dosage was based in a previous study showing that a
similar dose increased cellular L-arginine content in lungs of
ovalbumin-exposed mice [44]. Sildenafil dosing was based on
studies showing that similar doses given orally or subcutaneously
improved recovery after stroke in rats [45,46]. NaNO2 dose was
calculated to release, in the presence of deoxyhemoglobin,
potentially the same amount of NO as 1 mg of DPTA-NO using
the following reaction: NO2
2 (nitrite)+HbFe
2+ (deoxyhemoglo-
bin)+H
+RHbFe
3+ (methemoglobin)+NO+OH
2 [34].
Preparation and implantation of Alzet osmotic pumps
We also used an alternative method of L-arginine delivery using
osmotic pumps (Alzet, Cupertino, CA) to achieve a continuous
delivery of 200 mg/kg/day of L-arginine during the first 6 days of
infection. Osmotic pumps (model 1003D, constant delivery rate of
1 mL/hour for 3 days) were filled with the appropriate solution
(160 mg/ml of arginine or saline as control – 100 mL final volume)
and primed in 0.9% sterile saline at 37uC for approximately
4 hours to ensure immediate delivery of the contents after
implantation. Mice were anesthetized using isofluorane and the
primed pumps were implanted subcutaneously on the back,
slightly posterior to the scapulae, under sterile conditions in the
same day of infection. Pumps were changed on day 3 post
infection. A bolus injection of L-arginine (4 mg/mouse) or saline
was given IP just after implantation to a rapid establishment of a
steady state condition.
Hematocrit, plasma nitrite and exhaled NO
Hematocrit levels were measured in blood samples (20 ml) on
day 6 post infection using heparinized micro-hematocrit capillary
tubes (Chase, Rockwood, TN). Plasma nitrite content was
measured using an ENO-20 NOx Analyzer (Eicom, San Diego,
CA) according to the manufacturer’s instructions. Plasma samples
(20 ml) collected on day 6 twelve hours after the previous dose of
any given treatment were mixed with the same volume of
methanol using a vortex for 10 sec, centrifuged at 10,000 G for
10 min and the supernatant was collected and frozen (280uC)
until reading. Levels of exhaled NO were measured using a NOA
280i NO analyzer (Sievers, Boulder, CO) one hour after the
morning treatment on day 5 post infection. Mice were placed in a
custom plexiglas chamber for one min and, after this period, the
NO content of one sample of the chamber’s air was measured.
Cardiovascular parameters
Remote measurement of heart rate and blood pressures
(systolic, diastolic, pulse, and mean arterial pressures) was made
with Data System International telemetry devices (DSI, St. Paul,
MN) on individually housed mice at room temperature as
previously described [47]. During sterile surgery, the catheter tip
of a TA11PA-C20 unit was inserted into the carotid artery of the
anesthetized mouse (xylazine 10 mg/Kg and ketamine 150 mg/
Kg, IP) and the transmitter was secured in a subcutaneous pocket
in the dorsal neck region. Mice were allowed to recover for at least
5 days post surgery and all measurements were carried out in the
home-cage environment. Data were collected during a 30 min
baseline period after which an IP injection of the drug was given
and parameters were followed during the next hour (experimental
period). During the baseline and experimental periods mice were
left alone in the procedure room providing a noise free
environment. Heart rate, systolic, diastolic, and pulse pressures
data were averaged as 10 seconds bins for each animal and the
average for each bin from the same time point in each treatment
group was determined. Means from bins representing the first
30 minutes before injection were then averaged to calculate a
baseline for each group. Data from each bin was converted and
plotted as percentage of baseline.
Statistical analysis
Results were expressed as means and standard errors of the
mean unless otherwise stated. The log-rank test was used to
compare the different survival curves (Figures 1A, 1G, 2A, and
3A). Two-way repeated measurement ANOVA with Bonferroni
posttests was used to analyze parasitemia curves (Figures 1B, 2B,
and 3B). Kruskal-Wallis test with Dunn’s Multiple Comparison
post tests were used when comparing if one parameter varied
among three or more different treatment groups (Figures 1C–1F,
2C–2D, and 3C–3F). Mann-Whitney test was used when just two
groups were analyzed (Figures 1H). When combined prophylactic
treatments and multiple concentrations of DPTA-NO or sildenafil
were tested, post-tests to check for linear trend following Kruskal-
Wallis test were also performed (Figures 1F, 3D and 3F). A p-
value,0.05 was considered significant. Lowess curves were
calculated for the cardiovascular parameters to show the trend
of the data in each group. Normal ranges for each parameter were
calculated based in values obtained from four saline treated
animals. The range of values falling within the mean plus and
minus two standard deviations (SD) was considered normal and
treatments that decrease or increase the parameter values outside
this range were considered to affect the parameter (Figures 4A–
4E). All statistics were calculated using GraphPad Prism 4.01
(GraphPad Software, San Diego, CA).
Results
Strategies to increase L-arginine availability or improve
NOS activity did not prevent ECM
We first attempted to prevent ECM in PbA-infected mice by
addressing the possibility that low NO bioavailability is related to
hypoargininemia, whether or not caused by increased arginase
activity, or NOS dysfunction caused by BH4 deficiency. The
strategies consisted of supplementing arginine and/or BH4, with
or without inhibition of arginase. However, none of these
NO-Based Strategies to Prevent Cerebral Malaria
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to decrease mortality in PbA-infected mice in the doses and
schedules used (Figure 1A). The prophylactic treatments did not
change the course of parasitemia (Figure 1B) or the clinical status
of the mice during infection, as verified by rectal temperature
(Figure 1C) and motor behavior (Figure 1D) on day 6 of infection.
We determined the levels of exhaled NO in mice of groups that
received L-arginine, nor-NOHA or the combination of L-
arginine+nor-NOHA, but no significant changes in exhaled NO
levels were observed when compared with uninfected controls or
animals prophylactically treated with saline (Figure 1E). Compar-
atively, mice that received 1 mg of DPTA-NO showed very high
levels of exhaled NO (Figure 1E). Although exhaled NO level
measurements in mice can detect substantial changes in NO
bioavailability, it may not be sensitive enough to detect more
subtle variations as well as increases in cumulative NO production
[48]. Therefore, we measured plasma nitrite levels on day 6 post
infection. Mean plasma nitrite levels in all groups were
significantly higher than in the saline group (Figure 1F), indicating
that NO production was improved by these prophylactic
treatments. Mean plasma nitrite levels of mice prophylactically
treated with L-arginine+nor-NOHA+BH4 was higher than those
of mice that received nor-NOHA+L-arginine and the latter was
higher than those of mice that received only nor-NOHA. This
trend was statistically significant (Figure 1F) indicating that the
treatments had an additive effect. However, these subtle increases
in NO availability were not sufficient to prevent the development
of ECM.
Failure to keep plasma concentrations of L-arginine constantly
above a therapeutic threshold during the course of infection could
Figure 2. PDE-5 inhibition with sildenafil or sodium nitrite (NaNO2) supplementation did not prevent ECM. Cumulative survival (A),
course of parasitemia (B), rectal temperature (C), and motor behavior score (D) of PbA-infected mice prophylactic treated with saline (n=28), NaNO2
(n=13), and sildenafil at 0.1 (n=19), 0.01 (n=12) or 0.001(n=5) mg/mouse. Rectal temperature and motor behavior score were measured on day 6 of
infection. There were no significant differences in the parameters analyzed (p.0.05 for all comparisons).
doi:10.1371/journal.pone.0032048.g002
Figure 1. L-arginine and/or tetrahydro-L-Biopterin (BH4) supplementation combined or not with arginase inhibition did not
prevent ECM. Cumulative survival (A), course of parasitemia (B), rectal temperature (C), and motor behavior score (D) of PbA-infected mice treated
with bolus injections of saline (n=22), L-arginine 4 mg/mouse (n=9), the arginase inhibitor Nv-hydroxy-nor-Arginine (nor-NOHA) 250 mg/mouse
(n=15), BH4 1 mg/mouse (n=9), nor-NOHA+L-arginine (n=16), and nor-NOHA+L-arginine+BH4 (n=9). Rectal temperature and motor behavior score
were measured on day 6 of infection. Exhaled NO (E) from selected groups was measured 1 hour after the morning treatment on day 5 of infection
(n$5 per group). Plasma nitrite (F) from selected groups treated with bolus injections. Cumulative survival (G) and plasma nitrite (H) of PbA-infected
mice prophylactic treated with continuous L-arginine or saline supplementation using implanted osmotic pumps (n=10 per group). Plasma nitrite (F,
H) was measured on samples collected prior to the morning dosing on day 6 of infection (n$5 per group). *p,0.05, **p,0.01, ***p,0.001, arrows
indicate the presence of a linear trend.
doi:10.1371/journal.pone.0032048.g001
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tion used in preventing ECM. Nonetheless, supplementation of L-
arginine with the same daily dose used for bolus injection given
continuously using osmotic pumps did not improve survival
(Figure 1G), incidence of ECM, course of parasitemia, or clinical
status (verified by rectal temperature and motor behavior) of PbA-
infected mice when compared to infected control mice. Plasma
nitrite levels on day 6 post infection were significantly higher in L-
arginine supplemented mice than saline controls as revealed when
comparing absolute values (Figure 1H) and the delta nitrite
(difference between the day 6 and baseline – day 0 – values). Mean
baseline nitrite concentrations in plasma were not different
between saline and L-arginine supplemented groups.
Sodium nitrite or sildenafil prophylactic treatments do
not prevent ECM
It has been experimentally [31,32] and clinically [33,34] shown
that deoxygenated hemoglobin in an acidic environment reduces
nitrite to NO causing vasodilation. This effect may have an
important function in providing NO in sites of low oxygenation,
such as in ischemia. As ECM mice present vasospasm and regional
deficits of blood flow in the brain and their adjunctive treatment
with a vasodilator is capable of improving prognosis [14], we
reasoned that prophylactic NaNO2 administration would be able
to generate NO in such ischemic sites ameliorating microcircu-
latory parameters and decreasing mortality. However, there was
no significant difference in mortality and parasitemia between
mice that received or not NaNO2 (Figure 2A–2B), nor in rectal
temperature or motor behavior (Figure 2C–2D), showing that the
prophylactic treatment did not prevent ECM.
Sildenafil increases brain cGMP levels through inhibition of
PDE-5 [30], providing a method to optimize the L-arginine-NOS-
NO pathway so that smaller amounts of NO can still have proper
physiological effects. Based on this premise, we tested whether the
prophylactic treatment with sildenafil could prevent the develop-
ment of ECM. However, even at higher doses (0.1 mg/mouse),
sildenafil did not change survival, course of parasitemia, rectal
temperature, or motor behavior (Figure 2A–2D).
Combined sildenafil administration markedly reduces the
amount of exogenous NO needed to prevent ECM
When given at the effective dose against ECM, DPTA-NO
causes marked hypotension and decreases hematocrit in mice
[15,16]. We asked whether prophylactic treatment with DPTA-
NO at much lower amounts (0.1 and 0.01 mg/mouse every
12 hours) could also be effective in preventing ECM having lower
side effects. This hypothesis was not confirmed, as while
prophylactic DPTA-NO treatment at 1 mg/mouse decreased
mortality and improved the behavior score on day 6 without
significantly changing the course of parasitemia, no significant
differences in survival, course of parasitemia, temperature and
motor behavior were observed between mice prophylactically
treated with lower doses of DPTA-NO and mice receiving saline
(Figures 3A–3D). However, prophylactic treatment with a lower
dose (0.1 mg/mouse) of DPTA-NO in combination with sildenafil
at 0.1 mg/mouse decreased mortality and improved motor
behavior to similar levels as observed with DPTA-NO at 1 mg/
mouse without significant changes in the course of parasitemia or
rectal temperature (Figures 3A–3D). Mice that received the
survival-improving doses of DPTA-NO (1 mg) or DPTA-NO
0.1 mg plus sildenafil (0.1 mg) presented high plasma nitrite levels
when compared with animals that received saline (Figure 3E),
showing an increase in the NO bioavailability in these groups. The
use of lower amounts of DPTA-NO allowed by the addition of
sildenafil also resulted in the avoidance of the adverse effect of high
DPTA-NO doses on hematocrit (Figure 3F).
Figure 3. PDE-5 inhibition with sildenafil decreases the amount of dipropylenetriamine NONOate (DPTA-NO) necessary to prevent
ECM. Cumulative survival (A), course of parasitemia (B), rectal temperature (C), and motor behavior score (D) of PbA-infected mice treated with saline
(n=29), DPTA-NO (1, 0.1 or 0.01 mg/mouse, n=10 per group), DPTA-NO+sildenafil (0.1 mg/mouse of each drug, n=18), and sildenafil (0.1 mg/
mouse, n=19). Plasma nitrite (E) and hematocrit (F) from selected groups were measured on samples collected prior to the morning dosing on day 6
of infection (n$5 per group). *p,0.05, **p,0.01, ***p,0.001, arrows indicate the presence of a linear trend.
doi:10.1371/journal.pone.0032048.g003
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sildenafil decrease the cardiovascular side-effects
observed with high doses of DPTA-NO
We evaluated whether the effects of DPTA-NO injection on
arterial pressure (systolic, diastolic, pulse and MAP) as well as on
heart rate would be avoided or minimized by decreasing the dose
in the presence or not of sildenafil (0.1 mg). Administration of
DPTA-NO 1 mg decreased MAP, systolic and diastolic pressure
levels to around 50% of baseline 10 minutes after injection and
these parameters were kept low during the observation period
(Figure 4A–4D). Interestingly, the pulse pressure decrease (defined
as systolic minus diastolic pressure) shows that the drug had a
greater effect on systolic than on diastolic pressure. Mice that
received DPTA-NO 0.1 mg, or sildenafil 0.1 mg/mouse showed a
less intense variation in these parameters, which were kept mostly
within the range observed in mice receiving only saline, or showed
a late decrease (Figure 4A–4D). Mice that received DPTA-NO
0.1 mg plus sildenafil 0.1 mg/mouse showed a delayed decrease in
systolic, diastolic, and mean arterial pressures, but pulse pressure
was kept within the normal range during all the observation period
(Figure 4A–4D). There were no significant differences in heart rate
curves of mice in the different groups and all of them were kept
within the normal range (Figure 4E).
Discussion
Low NO bioavailability has been implicated in the pathogenesis
of both human and experimental CM [15,16,20,49]. In the
present study, we show that in ECM: a) prophylactic therapies
aiming to increase the amount of L-arginine available for NOS
through L-arginine or BH4 supplementation, with or without
arginase inhibition, in single or combined therapies, increased NO
bioavailability but did not prevent ECM in the doses and schemes
used; b) nitrite supplementation or PDE-5 inhibition also did not
prevent ECM in the doses and schemes used; c) a high amount of
NO supplementation provided by a potent NO-donor is necessary
to prevent the disease, but this amount can be reduced when
combined with a PDE-5 inhibitor; d) the combined sildena-
fil+DPTA-NO (0.1 mg of each drug) prophylactic therapy did not
present all the adverse effects observed in the prophylactic
treatment with the high dose of DPTA-NO alone.
There are numerous potential explanations for the failure of the
NO-promoting strategies used in this study in preventing ECM.
One consideration is that the prophylactic agents were not
administered in sufficient amounts to achieve therapeutic levels
during a sufficient period. The doses chosen for L-arginine, nor-
NOHA and BH4 were similar or even higher than those used in
previous studies showing their pharmacodynamic effects on
relevant parameters such as reversal of endothelial dysfunction
Figure 4. PDE-5 inhibition with sildenafil does not increase
dipropylenetriamine NONOate (DPTA-NO) side-effects in car-
diovascular parameters. Changes in mean arterial pressure (MAP, A),
systolic pressure (B), diastolic pressure (C), pulse pressure (D) and heart
rate (E) following one IP injection of saline (black dots and lines), DPTA-
NO (1 and 0.1 mg/mouse, red and blue dots and lines, respectively),
sildenafil (0.1 mg/mouse, green dots and lines), and DPTA-NO+sildenafil
(0.1 mg/mouse of each drug, purple dots and lines). Vertical doted lines
represent the time when the IP injection was given and separate the
baseline period from the experimental period. Results are expressed as
the percentage change in relation to the mean of the baseline period
for each group. Horizontal doted lines represent the range of values
falling within the mean plus and minus two standard deviations (SD) of
the baseline value calculated for saline treated group. n=4 per group.
doi:10.1371/journal.pone.0032048.g004
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(BH4, [40,41]) or arginase inhibition in a model of asthma (nor-
NOHA, [44]). However, we have not performed pharmacokinetic
studies of the compounds we used. In normal rats intravenous
injection of 0.1 mmol of L-arginine (57 mg/kg) induces a transient
(60 minutes) increase in plasma levels but sustained (more than
8 hours) increase in brain levels [38,39]. In addition, DPTA-NO
prevents ECM despite its short period (less than four hours) in the
bloodstream after IP injection [16], indicating that it is not
necessary to keep high levels of NO during long periods of time to
prevent ECM. On the other hand, pharmacokinetics varies among
species and malaria infection can change the pharmacokinetic
profile of compounds as it has been shown for L-arginine [50].
The fact that the injection of L-arginine, BH4 and/or nor-
NOHA did not result in increased levels of exhaled NO might
suggest in principle that the compounds were not properly
absorbed or these doses were insufficient to induce plasma levels
and tissue distribution compatible with the generation of
detectable levels of NO. This concern is particularly relevant for
L-arginine since a similar dose given to patients with severe
malaria was able to increase exhaled NO levels by 55% [19].
However, there are a number of factors to consider: 1)
methodologically, the volume of exhaled air and its NO content
are much higher in humans facilitating detection of relatively small
differences between groups [51]. In mice, although exhaled NO
level measurements can detect marked changes in NO bioavail-
ability (e.g., after DPTA-NO injection), it may not be sensitive
enough to detect more subtle variations as well as increases in
cumulative NO production [48]; 2) Timing is important. In the
study by Yeo et al. [19], exhaled NO was measured at a single
point at the end of the 30-minute L-arginine infusion and detected
a mean 55% increase in exhaled NO, but it is not known for how
long these levels were maintained. In mice, we measured exhaled
NO levels one hour after an intraperitoneal bolus injection and
because the baseline levels in mice were already low (3–5 PPB),
small and/or transient increases might be harder to detect; 3) The
increase in exhaled NO after L-arginine infusion was obtained in
patients with moderately severe malaria, whose plasma levels of
NO-quenching acellular hemoglobin is high but yet less than half
those seen in patients with severe malaria (2.6 versus 5.4 uM,
respectively - [19]). It is not know whether L-arginine infusion
would have the same effect in the latter group since free
hemoglobin stoichiometrically consumes micromolar quantities
of NO [52,53]. In mice, mean acellular plasma hemoglobin levels
also increase with disease severity (plasma levels of about 3 uM on
day 4 and 7 uM on day 6 of infection - [16]).
For these reasons, plasma nitrite levels are likely to be a more
reliable indicator of the efficacy of compound delivery. Indeed, all
prophylactically treated groups (L-arginine when given in bolus or
continuous delivery, and bolus injections of nor-NOHA, BH4 and
the combinations) showed increased plasma nitrite levels com-
pared to PbA-infected mice receiving saline (Figures 1F and 1H).
Moreover, treatments were additive, with a significant trend for
higher nitrite levels in groups receiving two (L-arginine+nor-
NOHA) or three (L-arginine+nor-NOHA+BH4) compounds. In
addition, it is important to stress that the plasma nitrite
measurements in groups treated with bolus injection were made
12 hours after dosing (day 6 in the morning, dose received on day
5 in the evening), therefore showing that these are not just
transient increases in nitrite levels, but correspond to lasting
increased production of NO. Therefore, we may conclude that the
bolus injections of L-arginine and/or nor-NOHA combined or not
with BH4 supplementation, resulted in increased NO bioavail-
ability, but this was not enough to prevent ECM. Indeed, plasma
nitrite levels achieved by L-arginine and/or BH4 supplementa-
tion, with or without arginase inhibition, were increased but not to
same degree as those attained by prophylactic treatment with
DPTA-NO or DPTA-NO plus sildenafil (see Figure 3E).
The half-life of L-arginine is shorter in patients with malaria
when compared to healthy adults [50] and a similar situation could
occurinPbAinfected mice,whichcouldexplainthe inefficacyofthe
L-arginine prophylactic treatment to prevent ECM. We tried to
accomplish enhanced NO production using an improved method
for L-arginine delivery with subcutaneous osmotic pumps, which
allow its continuous infusion. Although this method also resulted in
increased plasma nitrite levels on day 6 of infection (Figure 1H) this
scheme did not prevent ECM, suggesting that the fact that animals
were supplemented with bolus injection was not the single factor
responsible for the inefficacy of L-arginine supplementation in
preventing ECM. Nevertheless, we do not discard the possibility
that higher doses of L-arginine, with or without association with
other compounds, could be effective to generate the high levels of
NO needed to prevent ECM.
Other circumstancescanbe claimedto explain the failureofmost
treatments to prevent ECM. L-arginine is used as a substrate by five
different sets of enzymes: a) arginyl-tRNA synthetase; b) NO
synthases; c) arginases; d) arginine:glycine amidinotransferase; and
e) arginine decarboxylase [23]. We showed that it is possible to
increase the production of nitrite, indicative of NOS activity, during
theinfectionbythetreatmentwitha non-selectivearginaseinhibitor
associated or not with L-arginine supplementation. This indicates
that a deficiency of L-arginine due to arginase consumption occurs
in ECM, but the possible indirect consumption of L-arginine by the
other three pathways was not ruled out. Of particular interest is the
enzyme arginine decarboxylase, which synthesizes agmatine, an
endogenous neuromodulator induced in response to stress and/or
inflammation, that increases the expression of eNOS, irreversibly
inhibits nNOS, and downregulates iNOS [54,55,56]. It remains to
be shown whether a potential increase in activity of such enzymes
interferes with the total NO generation in ECM. Intracellular L-
arginine transport through the cationic amino acid transporters can
also regulate substrate availability for NOS [24]. Downregulation of
these transporters during the infectionalsocould explainthe failures
in the treatments.
NOS activity is inhibited in ECM [26], but the mechanism of
inhibition is unknown. We hypothesized that hypoargininemia due
to L-arginine consumption by arginase and/or BH4 deficiency
might play a role in NOS malfunction in ECM. The fact that the
combined injection of L-arginine+nor-NOHA+BH4 induced
higher levels of plasma nitrite than L-arginine+nor-NOHA and
that these two combinations induced levels higher than each
compound separately suggests that increased arginase activity and
eNOS uncoupling both contribute to impaired NO production in
ECM. Regulation of NOS is complex and dependent on several
co-enzymes (such as NADPH, flavin adenine dinucleotide and
flavin mononucleotide) and co-factors (BH4, calmodulin, heme,
and calcium) and their activity can be regulated by several kinases,
phosphatases and the endogenous competitive inhibitor asymmet-
rical dimethylarginine (ADMA) [48,57]. Indeed, plasma levels of
ADMA are increased in patients with severe malaria when
compared to healthy controls and were an independent predictor
of mortality in these patients [22]. The plasma L-arginine/ADMA
level ratio has been considered an important factor leading to
eNOS inhibition in malaria and sepsis [22,58]. In ECM, plasma
ADMA levels have been shown to decrease instead of increase
[16], which may be considered an intrinsic difference between
HCM and the murine model. However, the plasma L-arginine/
ADMA level ratio is also decreased in ECM and this measure may
NO-Based Strategies to Prevent Cerebral Malaria
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than its absolute plasma levels. Therefore, deficiency of other co-
enzymes and co-factors, decrease of L-arginine/ADMA ratio
during infection or mechanisms involving kinases and phospha-
tases can also be involved in the phenomenon.
The failure of sildenafil alone in preventing ECM may as well
be due to insufficient amounts being delivered or could be
explained based on data from erectile dysfunction studies showing
that PDE-5 inhibitors have no effect when the concentrations of
NO and cGMP are very low [29,59], which is the case of mice
presenting ECM [16]. This last interpretation is in line with our
demonstration that when co-administered with an NO-donor
sildenafil shows a protective effect against ECM development. In
this sense, the amount of exogenous NO provided by the injection
of 0.1 mg of DPTA-NO would generate the critical signaling
through cGMP formation which by itself, at this concentration,
would be insufficient to prevent ECM, but became effective with
the extended potency provided by PDE-5 inhibition. The
synergism between the two drugs is also apparent regarding their
effects on cardiovascular parameters, since a late decrease in blood
pressure was observed with the drug combination but not with
each drug independently at the same concentrations. The finding
that the combination of lower doses of DPTA-NO with sildenafil is
able to increase NO bioavailability as shown by increased plasma
nitrite levels and to decrease ECM incidence brings new prospects
for the use of NO donors in severe malaria, the combination being
an alternative to reduce the potent side effects secondary to the
injection of large amounts of DPTA-NO. Although it still affected
blood pressure, there was a considerable delay in relation to
DPTA-NO alone at high dose. In addition, the lower dose of
DPTA-NO, with or without sildenafil, prevented its deleterious
effects on hematocrit. It is therefore possible to envisage
manipulations in the treatment strategy to further minimize its
cardiovascular effects (e.g., administering first the DPTA-NO at
low dose with a later dose of sildenafil to potentiate the low
amounts of NO still present after some time of DPTA-NO
administration).
We also showed that the treatment with sodium nitrite did not
prevent ECM. The rationale for this treatment was based on
studies showing that nitrite would function as an ‘‘on demand’’
NO donor in inflammatory compromised brain vessels that would
present low pH and O2 concentration [31,32,33,34]. Although
these features are present in ECM, if NO generation from sodium
nitrite oxidation occurred, it was not sufficient to modify the
course of the disease.
In summary, the present study indicates that prophylactic
strategies based on NO restoration to improve the outcome of
ECM may be more complicated than originally envisaged. L-
arginine supplementation alone or associated with secondary
strategies such as arginase blockade and BH4 supplementation
were able to increase NO bioavailability but were shown to be
ineffective in preventing ECM in the doses and schemes used.
Therefore, more research is necessary to determine not only the
efficacy of alternative dosing and delivery systems but also to better
characterize the effect of interventions on relevant readouts such
as NO generation, endothelial function and activity of NOS
isoforms especially in the brain. On the other hand, our results
with the combination DPTA-NO at lower doses with sildenafil
indicates that NO-based prophylactic treatments can be optimized
to decrease potential side effects caused by the administration of
high doses of NO.
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